Zymeworks Inc. (NASDAQ:ZYME) Receives $35.70 Consensus Price Target from Analysts

Shares of Zymeworks Inc. (NASDAQ:ZYME) have been assigned an average recommendation of “Moderate Buy” from the fourteen ratings firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, ten have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $37.10.

Several equities research analysts recently issued reports on ZYME shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Zymeworks in a research note on Wednesday, January 21st. B. Riley Financial reiterated a “buy” rating and issued a $40.00 target price (up from $30.00) on shares of Zymeworks in a report on Friday, November 21st. Wells Fargo & Company upgraded shares of Zymeworks from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $25.00 to $33.00 in a report on Friday, December 12th. Citizens Jmp set a $32.00 price objective on shares of Zymeworks in a research report on Wednesday, December 3rd. Finally, HC Wainwright upped their price objective on shares of Zymeworks from $32.00 to $46.00 and gave the company a “buy” rating in a research note on Friday.

Insider Buying and Selling at Zymeworks

In related news, insider Paul Andrew Moore sold 20,110 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $25.10, for a total value of $504,761.00. Following the transaction, the insider directly owned 31,212 shares of the company’s stock, valued at approximately $783,421.20. This trade represents a 39.18% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Jeffrey T. L. Smith sold 10,538 shares of the business’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $25.10, for a total transaction of $264,503.80. Following the completion of the sale, the executive vice president owned 18,352 shares of the company’s stock, valued at $460,635.20. The trade was a 36.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 187,933 shares of company stock worth $4,673,716 in the last ninety days. Insiders own 33.51% of the company’s stock.

Institutional Trading of Zymeworks

Several hedge funds have recently added to or reduced their stakes in ZYME. EcoR1 Capital LLC boosted its stake in Zymeworks by 33.1% in the second quarter. EcoR1 Capital LLC now owns 22,970,388 shares of the company’s stock worth $288,278,000 after purchasing an additional 5,710,840 shares in the last quarter. Rubric Capital Management LP raised its holdings in shares of Zymeworks by 22.1% in the fourth quarter. Rubric Capital Management LP now owns 5,750,000 shares of the company’s stock valued at $151,398,000 after buying an additional 1,039,449 shares during the last quarter. Perceptive Advisors LLC lifted its position in Zymeworks by 56.0% during the 4th quarter. Perceptive Advisors LLC now owns 3,261,850 shares of the company’s stock worth $85,885,000 after buying an additional 1,171,187 shares in the last quarter. Vanguard Group Inc. lifted its position in Zymeworks by 8.1% during the 4th quarter. Vanguard Group Inc. now owns 2,328,727 shares of the company’s stock worth $61,315,000 after buying an additional 174,293 shares in the last quarter. Finally, Vestal Point Capital LP grew its holdings in Zymeworks by 53.5% during the 3rd quarter. Vestal Point Capital LP now owns 1,765,000 shares of the company’s stock worth $30,146,000 after acquiring an additional 615,000 shares during the last quarter. Institutional investors own 92.89% of the company’s stock.

Zymeworks Price Performance

ZYME stock opened at $24.08 on Wednesday. The firm has a market capitalization of $1.78 billion, a P/E ratio of -22.30 and a beta of 1.23. Zymeworks has a 52-week low of $9.03 and a 52-week high of $28.49. The company’s 50 day simple moving average is $23.72 and its 200-day simple moving average is $21.08.

Zymeworks (NASDAQ:ZYME) last announced its earnings results on Monday, March 2nd. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.20). Zymeworks had a negative net margin of 76.56% and a negative return on equity of 26.00%. The firm had revenue of $2.52 million for the quarter, compared to analyst estimates of $21.78 million. During the same period last year, the firm earned ($0.31) earnings per share. Zymeworks’s revenue for the quarter was down 91.9% compared to the same quarter last year.

Zymeworks News Roundup

Here are the key news stories impacting Zymeworks this week:

• Positive Sentiment: HC Wainwright raised its price target to $46 and reiterated a Buy rating — the new target implies substantial upside from current levels. Benzinga
• Positive Sentiment: Stifel Nicolaus boosted its price target to $47, another significant upward revision that supports a bullish view on ZYME’s longer‑term recovery. Stifel Target
• Positive Sentiment: Leerink Partners published a bullish forecast for Zymeworks, contributing to the cluster of upgrades and positive analyst sentiment this week. Leerink Report
• Neutral Sentiment: Lifesci Capital updated its FY-2026 and quarterly EPS forecasts with mixed changes: it materially improved the FY-2026 loss estimate (from -$1.40 to -$0.68) and sharply raised Q2/Q3 outlooks, but it lowered the Q1 estimate — a mixed signal that improves multi‑quarter visibility while acknowledging near‑term pressure. Lifesci Estimates
• Negative Sentiment: Recent quarterly results (reported March 2) showed a meaningful EPS miss and a ~92% YoY revenue decline, leaving Zymeworks unprofitable with negative margins — fundamentals that likely temper enthusiasm and explain part of the intraday weakness despite upgrades. Earnings Detail

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.